Payment overview · 2025
General Payments
$101.76
6 reported records · 5 companies
Healthcare provider profile · identity verified
Scott Kolander, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EWING, NJ · NPI 1942242748
Verified facts
What the public records show
CMS Open Payments records show Scott Kolander, M.D. received $101.76 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexium by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.14 | 36.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.00 | 19.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.92 | 16.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.23 | 14.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.47 | 13.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $101.76 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 519 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 59 |
| Eliquis | Apixaban | 378 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 56 |
| Losartan Potassium | Losartan Potassium | 304 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 56 |
| Gabapentin | Gabapentin | 293 | 48 |
| Mirtazapine | Mirtazapine | 241 | 29 |
| Sertraline Hcl | Sertraline Hcl | 241 | 30 |
| Furosemide | Furosemide | 223 | 38 |
| Memantine Hcl | Memantine Hcl | 212 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 19 |
| Potassium Chloride | Potassium Chloride | 129 | 25 |
| Buspirone Hcl | Buspirone Hcl | 128 | 12 |
| Lisinopril | Lisinopril | 128 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 18 |
| Trazodone Hcl | Trazodone Hcl | 120 | 20 |
| Myrbetriq | Mirabegron | 109 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 105 | 17 |
| Omeprazole | Omeprazole | 101 | 17 |
| Spironolactone | Spironolactone | 98 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 13 |
| Metformin Hcl | Metformin Hcl | 95 | 21 |
| Prednisone | Prednisone | 82 | 31 |
| Famotidine | Famotidine | 78 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 12 |
| Tramadol Hcl | Tramadol Hcl | 73 | 22 |
| Metformin Hcl Er | Metformin Hcl | 68 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 66 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 11 |
| Ezetimibe | Ezetimibe | 64 | 17 |
| Synthroid | Levothyroxine Sodium | 64 | 16 |
| Carvedilol | Carvedilol | 63 | 14 |
| Lorazepam | Lorazepam | 60 | 20 |
| Bumetanide | Bumetanide | 59 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 57 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 30 |
| Valsartan | Valsartan | 54 | 13 |
| Allopurinol | Allopurinol | 49 | 12 |
| Montelukast Sodium | Montelukast Sodium | 49 | 12 |
| Divalproex Sodium | Divalproex Sodium | 46 | suppressed |
| Jardiance | Empagliflozin | 46 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Alprazolam | Alprazolam | 44 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 40 | suppressed |
| Simvastatin | Simvastatin | 40 | 12 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 11 |
| Finasteride | Finasteride | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 13 |
| Memantine Hcl Er | Memantine Hcl | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Haloperidol | Haloperidol | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Metolazone | Metolazone | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 21 | suppressed |
| Benicar | Olmesartan Medoxomil | 21 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Diazepam | Diazepam | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Fentanyl | Fentanyl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Renacidin | Citric Ac/Gluconolact/Mag Carb | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Prolia | Denosumab | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Ativan | Lorazepam | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $101.76 · 6 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, TRELEGY ELLIPTA, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error